Skip to main content
HealthReportedHighDevelopingFeatured
7.2

Daraxonrasib trial shrinks pancreatic tumors; undetectable in 1 in 12 patients

Phase trial data for the KRAS-targeting pill daraxonrasib shows tumor shrinkage in nearly all 61 advanced pancreatic cancer patients, with undetectable disease in roughly 8%. This is a first-in-class oral therapy for a notoriously refractory cancer, though durability and survival benefit remain unproven at this early readout.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

Guardian Worldabout 7 hours agoGBengCredibility 29%View source

Score Breakdown

Mosaic Score7.2
Model confidence0.5
Significance0.8
Source credibility0.3
Source

Part of a situation

Related signals

8 found